David F. Claxton

This study shows that inhibiting acid ceramidase (AC) enhances venetoclax's effectiveness in venetoclax-resistant AML by inducing a cytotoxic integrated stress response.

This study identifies two sphingolipidomic subtypes in AML, with one subtype associated with poor clinical outcomes and high-risk features.

This study evaluates the anti-leukemic effects of LCL-805, an acid ceramidase inhibitor, in AML cell lines and patient samples, showing it promotes iron-dependent cell death by antagonizing Akt signaling.

This study evaluates optical genome mapping (OGM) for detecting genomic aberrations in AML, finding it identifies all clinically relevant SVs and CNVs and detects additional variants missed by standard methods.

The paper identifies numerous previously undetected structural variants in leukemia samples using integrated genome analysis and computational methods, revealing their impact on gene expression and patient survival.